This product is a fixed-ratio blend of three recovery research peptides, each of which has its own VialTalk monograph: BPC-157, TB-500, and KPV. It is sometimes extended with GHK-Cu and sold under names like "KLOW." The research interest in combining them is that each addresses a different phase of the tissue-healing cascade, so the blend is studied as a convergence of complementary mechanisms rather than as a single new molecule. This monograph summarises the components' roles, the rationale for combining them, and why a blend is harder to study than any single compound.
Chemical identity and structure.
The blend contains three distinct peptides at a fixed ratio set by the manufacturer: BPC-157 (a 15-amino-acid stable gastric pentadecapeptide derivative), TB-500 (the synthetic active fragment of Thymosin β4), and KPV (a C-terminal α-MSH tripeptide, Lys-Pro-Val). There is no single molecular weight or formula for the blend; each component retains its own identity and pharmacokinetics. See the individual VialTalk monographs for per-compound chemistry.
Mechanism of action.
The components act through distinct molecular pathways that overlap in theme (cytoprotection, inflammation control, regenerative signalling) but not in mechanism. BPC-157 is studied for angiogenesis, cytoprotection, and accelerated repair in tendon, muscle, gastrointestinal, and cardiovascular injury models. TB-500 (Thymosin β4) binds and sequesters G-actin, promoting cell migration, reducing fibrosis, and supporting regeneration in cardiac, muscular, ocular, and dermal models. KPV suppresses inflammatory signalling near its root, dampening NF-κB-driven cytokine production. The research rationale for the blend is temporal and spatial: inflammation is addressed at the source (KPV), local tissue repair and angiogenesis are driven (BPC-157), and reparative cell migration is mobilised more broadly (TB-500).
Research applications and the evidence base.
The evidence base for this product is per-component, not combination-level. Each constituent has its own (largely preclinical) injury-and-recovery literature, summarised in its individual monograph. There are no dedicated controlled trials of this three-peptide blend as a fixed formulation; the case for the combination rests on the components' separate mechanisms and on the general logic of covering multiple healing phases at once. That distinction should be kept explicit when reading any "blend" claim.
Human clinical trial data.
No human clinical trial has established administration parameters for the BPC-157 + TB-500 + KPV blend; VialTalk does not provide community-sourced dosing.
Storage and handling.
Store the lyophilized blend frozen (−20 °C); avoid freeze–thaw. A practical note for blends: the formulation is only as stable as its least-stable component, so default to the most conservative storage window among BPC-157, TB-500, and KPV.
Quality and COA considerations.
A meaningful COA for a blend must do more than a single-compound COA: it should confirm identity by mass spectrometry for each of the three peptides, report purity by HPLC, and — critically — report the ratio / proportion of each component, not just a single total mass. Many blend COAs report only total peptide mass; demand the per-component breakdown, because without it you cannot know how much of each peptide you are actually studying. Endotoxin should be reported for injection or tissue-contact models.
Research-use note: This monograph is an educational summary of the published research literature for the BPC-157 + TB-500 + KPV blend and its individual components. It is for laboratory and research use only. The evidence base is per-component and largely preclinical; there are no controlled trials of the fixed blend; and nothing here is medical advice.